Literature DB >> 25556265

The relationship between gene expression of Forkhead box C2 and tumor progression in cervical carcinoma.

Liqiong Cai1, Denghua Liu, Sisi Lu, Yuan Xu, Hongbo Wang.   

Abstract

To investigate the correlation between FOXC2 expression and human cervical cancer, the authors detected FOXC2 expression in cervical cancer cell lines, C33a, SiHa, and Hela. Moreover, FOXC2 expression was measured after TGF-beta1 treatment in C33a cells. Furthermore, the expression level of FOXC2 and microvessel density (MVD) were detected by indirect double-labeled immunofluorescence and laser scanning confocal microscopy in cervix tissue samples, 86 of cervical carcinoma, 54 of cervical intraepithelial neoplasia (CIN), and 30 of normal cervix as controls. The results showed that FOXC2 was expressed in all of the cell lines, and FOXC2 expression in C33a cells can be significantly up-regulated by the treatment of TGF-beta1 and the stimulus was highest when TGF-beta1 is five ng/ml. In cervix tissues, FOXC2 expression gradually increased during the transformation from normal to cancer, and this increase was significantly associated with tumor progression (p < 0.01), lymph node status (p < 0.01), and tumor grade (p < 0.05). FOXC2 expression was positively correlated with MVD (p < 0.05). These results suggest that FOXC2 may promote the development of cervical cancer via regulation of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25556265

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  2 in total

1.  Up-Regulation of FOXC2 and FOXQ1 Is Associated with The Progression of Gastric-Type Adenocarcinoma.

Authors:  Farzad Soleimani; Mohammadreza Hajjari; Bahram Mohammad Soltani; Mehrdad Behmanesh
Journal:  Cell J       Date:  2017-05-17       Impact factor: 2.479

2.  Role and importance of the expression of transcription factor FOXC2 in cervical cancer.

Authors:  Jing Wang; Xiujuan Yue
Journal:  Oncol Lett       Date:  2017-09-20       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.